Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy

2016 | journal article. A publication with affiliation to the University of Göttingen.

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Treatment with human immunoglobulin G improves the early disease course in a mouse model of Duchenne muscular dystrophy​
Zschuentzsch, J.; Zhang, Y.; Klinker, F.; Makosch, G.; Klinge, L.; Malzahn, D.   & Brinkmeier, H. et al.​ (2016) 
Journal of Neurochemistry136(2) pp. 351​-362​.​ DOI: 

Documents & Media


GRO License GRO License


Zschuentzsch, Jana; Zhang, Y.; Klinker, Florian; Makosch, Gregor; Klinge, Lars; Malzahn, Doerthe ; Brinkmeier, Heinrich; Liebetanz, David; Schmidt, Jens 
Duchenne muscular dystrophy (DMD) is a severe hereditary myopathy. Standard treatment by glucocorticosteroids is limited because of numerous side effects. The aim of this study was to test immunomodulation by human immunoglobulin G (IgG) as treatment in the experimental mouse model (mdx) of DMD. 2g/kg human IgG compared to human albumin was injected intraperitoneally in mdx mice at the age of 3 and 7weeks. Advanced voluntary wheel running parameters were recorded continuously. At the age of 11 weeks, animals were killed so that blood, diaphragm, and lower limb muscles could be removed for quantitative PCR, histological analysis and exvivo muscle contraction tests. IgG compared to albumin significantly improved the voluntary running performance and reduced muscle fatigability in an exvivo muscle contraction test. Upon IgG treatment, serum creatine kinase values were diminished and mRNA expression levels of relevant inflammatory markers were reduced in the diaphragm and limb muscles. Macrophage infiltration and myopathic damage were significantly ameliorated in the quadriceps muscle. Collectively, this study demonstrates that, in the early disease course of mdx mice, human IgG improves the running performance and diminishes myopathic damage and inflammation in the muscle. Therefore, IgG may be a promising approach for treatment of DMD.
Issue Date
Journal of Neurochemistry 
1471-4159; 0022-3042



Social Media